Your browser doesn't support javascript.
loading
Culprit plaque morphology determines inflammatory risk and clinical outcomes in acute coronary syndrome.
Gerhardt, Teresa; Seppelt, Claudio; Abdelwahed, Youssef S; Meteva, Denitsa; Wolfram, Christopher; Stapmanns, Philip; Erbay, Aslihan; Zanders, Lukas; Nelles, Gregor; Musfeld, Johanna; Sieronski, Lara; Stähli, Barbara E; Montone, Rocco A; Vergallo, Rocco; Haghikia, Arash; Skurk, Carsten; Knebel, Fabian; Dreger, Henryk; Trippel, Tobias D; Rai, Himanshu; Joner, Michael; Klotsche, Jens; Libby, Peter; Crea, Filippo; Kränkel, Nicolle; Landmesser, Ulf; Leistner, David M.
Afiliação
  • Gerhardt T; Department of Cardiology, Angiology and Intensive Care Medicine CBF, Deutsches Herzzentrum der Charité, Germany and Berlin Institute of Health (BIH), Hindenburgdamm 30, Berlin 12203, Germany.
  • Seppelt C; DZHK (German Centre for Cardiovascular Research), Partner Site, Berlin, Germany.
  • Abdelwahed YS; Cardiovascular Research Institute and the Department of Medicine, Cardiology, Icahn School of Medicine at Mount Sinai, USA.
  • Meteva D; Department of Cardiology, Angiology and Intensive Care Medicine CBF, Deutsches Herzzentrum der Charité, Germany and Berlin Institute of Health (BIH), Hindenburgdamm 30, Berlin 12203, Germany.
  • Wolfram C; DZHK (German Centre for Cardiovascular Research), Partner Site, Berlin, Germany.
  • Stapmanns P; Department of Medicine, Cardiology/Angiology, Goethe University Hospital, Frankfurt, Germany.
  • Erbay A; DZHK (German Centre for Cardiovascular Research), Partner Site Frankfurt Rhine-Main, Frankfurt, Germany.
  • Zanders L; Department of Cardiology, Angiology and Intensive Care Medicine CBF, Deutsches Herzzentrum der Charité, Germany and Berlin Institute of Health (BIH), Hindenburgdamm 30, Berlin 12203, Germany.
  • Nelles G; DZHK (German Centre for Cardiovascular Research), Partner Site, Berlin, Germany.
  • Musfeld J; Department of Cardiology, Angiology and Intensive Care Medicine CBF, Deutsches Herzzentrum der Charité, Germany and Berlin Institute of Health (BIH), Hindenburgdamm 30, Berlin 12203, Germany.
  • Sieronski L; DZHK (German Centre for Cardiovascular Research), Partner Site, Berlin, Germany.
  • Stähli BE; Department of Cardiology, Angiology and Intensive Care Medicine CBF, Deutsches Herzzentrum der Charité, Germany and Berlin Institute of Health (BIH), Hindenburgdamm 30, Berlin 12203, Germany.
  • Montone RA; Department of Cardiology, Angiology and Intensive Care Medicine CBF, Deutsches Herzzentrum der Charité, Germany and Berlin Institute of Health (BIH), Hindenburgdamm 30, Berlin 12203, Germany.
  • Vergallo R; Department of Cardiology, Angiology and Intensive Care Medicine CBF, Deutsches Herzzentrum der Charité, Germany and Berlin Institute of Health (BIH), Hindenburgdamm 30, Berlin 12203, Germany.
  • Haghikia A; DZHK (German Centre for Cardiovascular Research), Partner Site, Berlin, Germany.
  • Skurk C; Department of Medicine, Cardiology/Angiology, Goethe University Hospital, Frankfurt, Germany.
  • Knebel F; DZHK (German Centre for Cardiovascular Research), Partner Site Frankfurt Rhine-Main, Frankfurt, Germany.
  • Dreger H; Department of Cardiology, Angiology and Intensive Care Medicine CBF, Deutsches Herzzentrum der Charité, Germany and Berlin Institute of Health (BIH), Hindenburgdamm 30, Berlin 12203, Germany.
  • Trippel TD; DZHK (German Centre for Cardiovascular Research), Partner Site, Berlin, Germany.
  • Rai H; Department of Medicine, Cardiology/Angiology, Goethe University Hospital, Frankfurt, Germany.
  • Joner M; DZHK (German Centre for Cardiovascular Research), Partner Site Frankfurt Rhine-Main, Frankfurt, Germany.
  • Klotsche J; Department of Cardiology, Angiology and Intensive Care Medicine CBF, Deutsches Herzzentrum der Charité, Germany and Berlin Institute of Health (BIH), Hindenburgdamm 30, Berlin 12203, Germany.
  • Libby P; Department of Cardiology, Angiology and Intensive Care Medicine CBF, Deutsches Herzzentrum der Charité, Germany and Berlin Institute of Health (BIH), Hindenburgdamm 30, Berlin 12203, Germany.
  • Crea F; DZHK (German Centre for Cardiovascular Research), Partner Site, Berlin, Germany.
  • Kränkel N; Klinik für Kardiologie, Universitäres Herzzentrum, Universitätsspital Zürich, Zurich, Switzerland.
  • Landmesser U; Department of Cardiovascular Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  • Leistner DM; Department of Cardiovascular Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Eur Heart J ; 44(38): 3911-3925, 2023 10 12.
Article em En | MEDLINE | ID: mdl-37381774
ABSTRACT

AIMS:

Rupture of the fibrous cap (RFC) and erosion of an intact fibrous cap (IFC) are the two predominant mechanisms causing acute coronary syndromes (ACS). It is uncertain whether clinical outcomes are different following RFC-ACS vs. IFC-ACS and whether this is affected by a specific inflammatory response. The prospective, translational OPTIcal-COherence Tomography in Acute Coronary Syndrome study programme investigates the impact of the culprit lesion phenotype on inflammatory profiles and prognosis in ACS patients. METHODS AND

RESULTS:

This analysis included 398 consecutive ACS patients, of which 62% had RFC-ACS and 25% had IFC-ACS. The primary endpoint was a composite of cardiac death, recurrent ACS, hospitalization for unstable angina, and target vessel revascularization at 2 years [major adverse cardiovascular events (MACE+)]. Inflammatory profiling was performed at baseline and after 90 days. Patients with IFC-ACS had lower rates of MACE+ than those with RFC-ACS (14.3% vs. 26.7%, P = 0.02). In 368-plex proteomic analyses, patients with IFC-ACS showed lower inflammatory proteome expression compared with those with RFC-ACS, including interleukin-6 and proteins associated with the response to interleukin-1ß. Circulating plasma levels of interleukin-1ß decreased from baseline to 3 months following IFC-ACS (P < 0.001) but remained stable following RFC-ACS (P = 0.25). Interleukin-6 levels decreased in patients with RFC-ACS free of MACE+ (P = 0.01) but persisted high in those with MACE+.

CONCLUSION:

This study demonstrates a distinct inflammatory response and a lower risk of MACE+ following IFC-ACS. These findings advance our understanding of inflammatory cascades associated with different mechanisms of plaque disruption and provide hypothesis generating data for personalized anti-inflammatory therapeutic allocation to ACS patients, a strategy that merits evaluation in future clinical trials.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndrome Coronariana Aguda / Placa Aterosclerótica Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Eur Heart J Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndrome Coronariana Aguda / Placa Aterosclerótica Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Eur Heart J Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha